Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.

 

Recent news :

Nov 2024 – Affilogic is presenting at the next I4ID congressPerring Jacquot is presenting latest data on anti-influenza Nanofitin®-based therapeutics. Pulmonary delivered anti-influenza Nanofitins® exert very promising efficacy results in-vivo in mice.

Nov 2024 – Affilogic CSO Mathieu Cinier is presenting at PEGS Europe 2025: Mathieu will present new approaches using Nanofitins® to treat infectious disease. Nanofitin® alternative scaffold generation platform allows for the generation of therapeutic candidates of high neutralisation potential in roughly 100 days, and can be amenable to local treatment in the case of pulmonary diseases.

Around the world

BiotechShowcase 2025

BiotechShowcase 2025

Affilogic will attend next BiotechShowcase in San-Francisco – USA
Jan 13-15, 2025

Visit the event website

I4ID Lyon 2024

I4ID Lyon 2024

Affilogic presenting at 8th I4ID in Lyon – France
Nov 27-28, 2024

Visit the event website

BIO EUROPE 2024

BIO EUROPE 2024

Affilogic will attend next BIO EUROPE in Stockholm – Sweden
Nov 4-6, 2024

Visit the event website

Nanofitins

Our Programs

NanoVector